Blincyto (blinatumomab) / Astellas, Amgen, BeOne Medicines - LARVOL DELTA

THE LIFELINE WITHIN REACH? THE FIGHT FOR ESSENTIAL MEDICINES IN KENYA (SIOP 2026) - "Three modern medicines—rituximab, blinatumomab, and pegaspargase—are used as case studies to illustrate the consequences of exclusion from the national list. The gap between basic and modern cancer care in Kenya is not merely a supply issue but reflects deeper systemic barriers, including slow EML updates, high drug costs, and weak procurement systems. Urgent action is needed: accelerated EML revisions, aggressive price negotiations, and global advocacy for equitable access. Closing this innovation gap is a moral imperative to ensure every child, regardless of birthplace, has a fighting chance at survival."

MRD RESPONSE AND TOXICITY OF ADAPTED BFM-2009 THERAPY IN HIGH-RISK PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTRE EXPERIENCE FROM INDIA (SIOP 2026) - "Blinatumomab, due to limited availability, was used for patients with persistent MRD, unable to tolerate further intensive chemotherapy...Vincristine-induced Neuropathy was the commonest chemotherapy- related toxicity (31.3%)... Outcomes of children with HR-ALL treated in resource-limited settings is affected by challenges with supportive care. MRD-guided intensification using an adapted BFM-2009 protocol achieved high rates of MRD-clearance and encouraging survival. Management tailored to balance treatment-related morbidity and disease-related mortality might improve survival."

Clinical • Acute Lymphocytic Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Pediatrics • Septic Shock • T Acute Lymphoblastic Leukemia

BLINOTUMOMAB IN ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN: RESULTS OF USE, NEW INDICATIONS, TOXICITY – DATA FROM REAL-WORLD CLINICAL PRACTICE. (SIOP 2026) - "Subsequently, treatment with low- dose methotrexate was continued on an outpatient basis according to the protocol.The following adverse events were observed during blinatumomab therapy: grade 2-3 neurotoxicity, manifested by seizures, occurred in 5 patients (11.1%); grade 2-3 allergic reactions occurred in 2 patients (4.4%); fever, requiring tocilizumab and antibiotic therapy, occurred in 6 patients (13.3%). Blinatumomab demonstrated high efficacy in achieving MRDnegativity and favorable survival rates in children with ALLinUzbekistan. Importantly,thedrug proved to be aneffective therapeutic option for patients for whom intensive induction chemotherapy was not possible due to severe infectious complications."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia

BLINATUMOMAB IN PAEDIATRIC ALL: NATIONAL EXPERIENCE FROM URUGUAY (SIOP 2026) - "Blinatumomab was effective, safe and operationally feasible across multiple indications, supporting its integration into paediatric ALL care and home-based delivery in resource-constrained settings."

Acute Lymphocytic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Pediatrics • KMT2A

MEASURABLE RESIDUAL DISEASE CAN ANTICIPATE RELAPSE AND GUIDE PREEMPTIVE THERAPY IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA. (SIOP 2026) - "In six cases, continuation of standard treatment or the initiation of additional therapies (mercaptopurine + ruxolitinib, blinatumomab + transplantation) successfully aborted the relapse, although in two of these cases, only temporarily. MFC, FISH, and PCR are complementary methods for monitoring MRD that can anticipate relapse. The frequency with which these methods anticipate relapse depends primarily on their sensitivity and the frequency of monitoring. Continuation of standard treatment or the initiation of additional therapies can abort relapse or, at least, modify its course."

Clinical • Residual disease • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Pediatrics

BLINATUMOMAB FOR RELAPSED/REFRACTORY PEDIATRIC B-ALL IN A RESOURCE-LIMITED SETTING: A SINGLE-CENTER EXPERIENCE FROM RABAT, MOROCCO (SIOP 2026) - "Blinatumomab can be safely administered in a resource-limited setting and may represent an effective bridge to HSCT in pediatric patients with relapsed or refractory B-ALL. However, high drug cost, prolonged hospitalization, and logistical constraints remain major barriers to wider implementation in low-resource environments."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Childhood B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Pediatrics

CD22 DIRECTED THERAPY OF REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (SIOP 2026) - "The use of anti-CD22 antibody- drug conjugates, such as inotuzumab ozogamicin (IO), achieves BM clearance in most patients, but is associated with significant side effects...In 6 cases a course of blinatumomab and in 5 cases chemotherapy preceded IO... IO has demonstrated high efficacy with moderate toxicity in pediatric patients with RR- B-ALL. IO therapy allows to achieve MRD-negative remission in most patients and provides bridging to HSCT/CAR-T therapy without significant toxicity."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • AFF1 • CD22 • KMT2A • MLLT3 • PAX5 • RUNX1

SAFETY AND CAREGIVER EXPERIENCE OF AMBULATORY BLINATUMOMAB IN PEDIATRIC B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (SIOP 2026) - "Outpatient administration of blinatumomab appears feasible and well accepted by caregivers. These findings highlight the importance of caregiver education and accessible medical support to ensure safe ambulatory immunotherapy."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Pediatrics

BLINATUMOMAB IN HIGH-RISK PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSE IN NORTHEAST BRAZIL: REAL-WORLD CLINICAL BENEFIT, HOSPITAL COST OFFSET, AND EARLY ECONOMIC VALUE SIGNALS (SIOP 2026) - "The cost-effectiveness of blinatumomab is highly dependent on treatment positioning. Its greatest value emerges when used in first high-risk relapses as a bridge-to-transplant strategy, enabling curative intent while reducing healthcare resource utilization. These findings provide early real-world evidence supporting the strategic incorporation of immunotherapy in resource-limited settings."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Pediatrics

HOME ADMINISTRATION OF BLINATUMOMAB USING CADD INFUSION PUMPS IN PEDIATRIC LEUKEMIA: A SAFE MODEL OF CARE DELIVERY AND TREATMENT HUMANIZATION (SIOP 2026) - "Home administration of blinatumomab using CADD pumps appears feasible and safe when supported by structured protocols and caregiver education. This approach may reduce hospitalization and healthcare costs while improving quality of life for pediatric patients and families. Implementation of home immunotherapy models may offer an opportunity for pediatric oncology centers, particularly in Latin America, to expand access to advanced therapies while promoting patient-centered care."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Pediatrics

BLINATUMOMAB ACHIEVES HIGH RATES OF MINIMAL RESIDUAL DISEASE CLEARANCE AND ENABLES TRANSPLANTATION IN PEDIATRIC AND AYA B CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN PERU (SIOP 2026) - "Blinatumomab achieved high MRD clearance rates and enabled bridging to HSCT in a substantial proportion of patients, supporting its role in high-risk pediatric and AYA B-ALL in resource- limited settings."

Clinical • Minimal residual disease • Residual disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Pediatrics • Transplantation

ADVERSE EVENTS ASSOCIATED WITH BLINATUMOMAB IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: EXPERIENCE FROM A REFERRAL CENTER IN COLOMBIA. (SIOP 2026) - "CRS was observed in 1 patient and resolved with dexamethasone. The frequency and profile of adverse events were consistent with published data. Most events occurred early during treatment. CRS was uncommon and manageable with corticosteroids."

Adverse events • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia • Movement Disorders

FROM INPATIENT DEPENDENCY TO OUTPATIENT CARE: DELIVERY OF BLINATUMOMAB IN CHILDREN IN A RESOURCE LIMITED SETTING (SIOP 2026) - "Structured multidisciplinary training enabled safe, scalable and sustainable delivery of blinatumomab in an LMIC pediatric oncology setting. Effective outpatient continuation, supported by timely management of treatment related complications, substantially reduced hospitalization burden while expanding access to blinatumomab."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Respiratory Diseases

CLINICAL PROFILE, RISK FACTORS AND OUTCOMES OF BLINATUMOMAB ASSOCIATED NEUROTOXICTY IN PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (SIOP 2026) - "Neurotoxicity occurred in about one-fourth of children receiving blinatumomab,occurred early in cycle-1, and was more likely in children 10 years and above. These rates are comparable to those reported from high-income countries. Most events were manageable with treatment interruption and dose modification, allowing successful rechallenge, though another one-fourth of toxic events required discontinuation."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Hematological Malignancies • Leukemia • Pediatrics

COMBINING MEDICAL PROCUREMENT AND ADVOCACY TO SECURE SUSTAINABLE ACCESS TO PEDIATRIC CANCER MEDICINES IN UKRAINE (SIOP 2026) - "Treatments unavailable in Ukraine – including blinatumomab, defibrotide, and midostaurin – were made accessible, helping avoid medical evacuation to EU countries and reducing pressure on their healthcare systems. Earlier, Tabletochki's advocacy contributed to expanding the national Essential List of Pediatric Anti-Cancer Medicines to include asparaginase Erwinia and thiotepa... By combining targeted medical procurement with advocacy and system-level engagement, Tabletochki helps children with cancer access medicines and supports redesign of centralized procurement to ensure sustainable access in the future. During the war, international support and funding remain essential to enable local NGOs to improve access to medicines."

Clinical • Oncology • Pediatrics

IMMUNE KINETICS FOLLOWING BLINATUMOMAB IN PEDIATRIC RELAPSED/ REFRACTORY B- ACUTE LYMPHOBLASTIC LEUKEMIA (SIOP 2026) - "This study demonstrates predictable immune responses to Blinatumomab: early T-cell redistribution, preferential CD8+ T-cell and EM subset expansion. Specific T-cell subset expansions may identify MRD-responders. Our study provides insights and potential immune-signatures that can correlate with responses in patients receiving immune-targeting therapies."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Pediatrics • CD8 • IFNG

MICRO-COSTING ANALYSIS FOR PEDIATRIC RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY IN THE UNITED STATES (SIOP 2026) - "Toxicity costs included the 20 most serious adverse events, estimated per episode and weighted by published clinical trial incidence to reflect expected toxicity burden by treatment arm. Total cost (% of upfront treatment vs downstream complications) for the 12 treatment approaches was: 1)CEC $158,558(66%,34%), 2)Clofarabine $151,932(65%,35%), 3) FLAG-IDA $184,230(72%,28%), 4)ALLR3 re-induction $324,186(79%,21%) 5)ALLR3 maintenance $147,358(65%,35%) 6)Allogeneic bone marrow transplant $381,249(47%,53%), 7)Blinatumomab $282,340(91%,9%), 8)Inotuzumab ozogamicin $139,652(70%,30%), 9-10)Academic-CAR-T outpatient $243,540(56%,44%) and inpatient 267,669(60%,40%), 11-12)Commercial-CAR-T outpatient $597,034(82%,18%) and inpatient 621,163(82%,18%). Per-episode toxicity costs ranged from $1,257 for anemia to $256,990 for transplant‑associated thrombotic microangiopathy, driven predominantly by eculizumab. This analysis provides the first comprehensive ingredient‑level costing of..."

Clinical • HEOR • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Pediatrics • Transplantation Associated Thrombotic Microangiopathy

MANAGEMENT OF DOWN SYNDROME B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST RELAPSE: RESULTS OF AN INTERNATIONAL SURVEY OF PEDIATRIC ONCOLOGISTS (SIOP 2026) - "For late medullary relapse, 46% would opt for definitive CAR-T and 51% would choose definitive chemo-immunotherapy (e.g., with blinatumomab/inotuzumab). CAR-T therapy plays an important role in first relapse DS B-ALL. Its evolving use as definitive therapy supports development of consensus guidelines. A prospective trial testing CAR-T in DS-ALL is strongly supported."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Pediatrics

BRINGING BLINATUMOMAB TO THE BEDSIDE: A QUALITATIVE LOOK AT MULTILEVEL CHALLENGES AND EMERGING INSIGHTS FROM CLINICIANS IN RESOURCE-VARIED SETTINGS (SIOP 2026) - "This study provides insights that move beyond feasibility to illuminate what enables or constrains equitable access to effective, complex immunotherapies. Our findings demonstrate essential contextual considerations for planning and scaling blinatumomab implementation in"

Clinical • Hematological Malignancies • Leukemia

OPTIMIZING SAFETY AND EFFICACY OF ASPARAGINASE AND BLINATUMOMAB THERAPY IN FRONTLINE ACUTE LYMPHOBLASTIC LEUKEMIA REGIMENS IN DIVERSE HEALTHCARE SETTINGS – INTERNATIONAL EXPERT CONSENSUS (SIOP 2026) - "Key consensus statements in each topic were as follows: 1. Optimal dosing of asparaginase and therapeutic drug monitoring (TDM) – a) Duration of asparagine depletion with adequate trough serum asparaginase activity prior to each subsequent dose is key to successful treatment; b) Dosage and administration interval must be considered together and dosing schedule should be determined by the total duration of asparagine depletion required for the treatment protocol; c) TDM is prioritized in patients with suspected hypersensitivity reaction (HSR) to differentiate it from infusion-related allergy-like reactions. 2."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • CD19

THE EFFECTIVENESS ANALYSIS OF BLINATUMOMAB IN CLEARING MINIMAL RESIDUAL DISEASE IN PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON NGS (SIOP 2026) - "Blinatumomab could further eradicate MRD after patients achieve MFC-MRD undetectable in pediatric B- ALL patients and with mild adverse reactions."

Clinical • Minimal residual disease • Next-generation sequencing • Residual disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Hypertension • Leukemia • Pediatrics

BLINATUMOMAB TO REPLACE FIRST-LINE BFM HIGH-RISK INTENSIFICATION IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN PEDIATRIC ALL: A RETROSPECTIVE REAL-WORLD COHORT FROM MEXICO (SIOP 2026) - "Standardization measures included fusion gene sequencing, prednisone during induction, deferred intrathecal therapy, and enhanced maintenance adherence monitoring. Incorporation of Blinatumomab to replace HR intensification within a standardized BFM 2017-based protocol is associated with substantially improved OS and EFS in pediatric ALL at a Mexican tertiary center, with an acceptable safety profile. These real-world data support prospective evaluation of immunotherapy-based de-escalation strategies in LMIC settings."

IO biomarker • Real-world • Real-world evidence • Retrospective data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Pediatrics

REAL-WORLD STUDY OF INOTUZUMAB OZOGAMICIN IN COMBINATION WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN (SIOP 2026) - "Although the advent of blinatumomab and CAR-T cell therapy has significantly improved clinical outcomes, a subset of patients continues to relapse post-immunotherapy, including those presenting with CD19-negative disease. Inotuzumab ozogamicin combined with chemotherapy is an effective salvage strategy for pediatric R/R B-ALL with a favorable safety profile. It serves as a viable and effective bridging regimen to HSCT. Hide"

Clinical • Combination therapy • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Childhood B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • CD22

Clinical Study Protocol for Stratified Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Guided by Multimodal MRD Monitoring (ChiCTR) - P4 | N=158 | Recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University

New P4 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance (clinicaltrials.gov) - P1/2 | N=64 | Recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase classification: P1 ➔ P1/2 | N=12 ➔ 64 | Trial completion date: May 2020 ➔ Jun 2025 | Trial primary completion date: May 2020 ➔ Jun 2025

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • KMT2A